Biotechnology group T-Therapeutics has secured a $32m (£24.3m) extension to its Series A round, bringing the total to £69.2m.
The University of Cambridge spinout is developing T cell receptor therapeutics for cancer and autoimmune disease.
New investors BGF and Tencent have joined the Series A round, which already includes Sofinnova Partners, F-Prime Capital, Digitalis Ventures, Cambridge Innovation Capital, Sanofi Ventures and the University of Cambridge.
“We are delighted to have significantly added to our Series A financing, which we see as a strong validation of both our technology and our progress to date,” said Theodora Harold, chief executive of T-Therapeutics.
“I would like to thank Tencent and BGF for their belief in our potential, as well as all our existing investors for their continued support.”
The company is primarily working on two drug development programmes, one targeting treatment for tumours and the other targeting harmful immune cells.
BGF partner Luke Rajah added: “This is a leadership team with an outstanding track record of building successful drug discovery businesses and translating science into medicines.
“Backed by a syndicate of world-class life sciences investors, T-Therapeutics is uniquely positioned to unlock previously undruggable targets with its first-in-class bispecifics. We are proud to support the team and help catalyse their programmes towards the clinic.”
